Global Vaccine Adjuvants Market to Grow Over 6% Annually Through 2028 Driven by Rising Demand and Focus on Human Vaccines
• Global vaccine adjuvants market valued at $0.72B in 2022, expects 6.56% CAGR through 2028 due to rising demand • North America leads market due to robust healthcare infrastructure, major pharma players, and strict evaluation • Human vaccine adjuvants and commercial applications are dominant segments amid focus on human vaccination programs • Comprehensive analysis examines various product types, market dynamics, trends, competitive landscape, and future outlook • Key players include Dynavax Technologies, GSK, Novavax, Agenus Inc., Merck KGaA, and Vaxine Pty Ltd